Cover Image
市場調查報告書

前列腺癌治療藥的全球市場

Prostate Cancer Therapeutics

出版商 Global Industry Analysts, Inc. 商品編碼 360715
出版日期 內容資訊 英文 337 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
前列腺癌治療藥的全球市場 Prostate Cancer Therapeutics
出版日期: 2016年05月01日 內容資訊: 英文 337 Pages
簡介

本報告提供全球前列腺癌治療藥的市場相關調查,提供您市場分析 (過去6年的實際成果值),產品概要,最近的市場活動,世界市場趨勢預測 (今後8年的預測值),各地區·主要國家市場詳細趨勢等分析,再加上主要企業簡介,為您概述為以下內容。

第1章 簡介·調查方法·產品定義

第2章 摘要整理

  • 產業概要
    • 序論
    • 由於新產品上市,前列腺癌治療藥市場急速成長
    • 荷爾蒙療法佔市場大半部分
    • 標靶治療:癌症治療的新境界
    • 放射治療:普及率上升
    • 藥物遞送的技術創新:產品差異化的主要因素
    • 新治療藥的出現
    • 小規模企業:民間資本投資的主對象
    • 低侵入性治療設備:新興國家市場的普及動向
    • 歐洲市場:社會認知度的上升促進市場
    • 成長推動因素
    • 阻礙成長的要素
  • 臨床實驗狀況
    • 開發平台候補藥
    • 前臨床階段的醫藥品
    • 已上市的醫藥品
  • 產品概要
    • 癌症:現代社會的最大健康問題
    • 前列腺結構
    • 前列腺癌:概要
    • 前列腺癌症檢查·發現方法
    • 前列腺癌檢驗·發現的推動策略
    • 前列腺癌的癌症分期 (分期)
    • 遺傳/非遺傳要素
    • 癌症的預防
    • 預防前列腺癌上飲食所扮演的角色
  • 前列腺癌的治療選擇
    • 荷爾蒙療法
    • 放射治療
    • 化療
    • 前列腺癌手術
    • 其他治療選擇
    • 選擇最適合的治療選擇
    • 復燃前列腺癌
      • 手術後的復發
      • 放射治療後的復發
      • 荷爾蒙難治前列腺癌 (HRPC)
      • 復發前列腺癌治療的推動策略
  • 新藥認證·臨床實驗的動向 (全38件)
  • 產品開發·銷售 (全8件)
  • 最近的產業活動 (全73件)
  • 主要企業分析 (計23公司)
  • 全球市場預測

第3章 市場

  • 美國
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 其他的歐洲各國
  • 其他的國家 (RoW)

第4章 競爭環境

目錄
Product Code: MCP-1747

This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Million by the following Segments: Hormone Therapy, and Other Therapies. The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 76 companies including many key and niche players such as -

AbbVie, Inc.
Æterna Zentaris Inc.
Allergan plc
Amgen Inc.
Astellas Pharma Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations

  • Disclaimers
  • Data Interpretation & Reporting Level
  • Product Definitions and Scope of Study
    • Hormonal Therapy
    • Radiation Therapy
    • Chemotherapy
    • Surgical Procedures
    • Other Treatment Options

II. EXECUTIVE SUMMARY

1. Industry Overview

  • A Prelude...
  • New Products to Bolster Sales of Prostate Cancer Therapeutics
  • Key Prostate Cancer Drugs & Companies
  • Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market
    • Table 1: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in the US for 2007 (includes corresponding Graph/Chart)
  • Select Prostate Cancer Hormonal Therapy Drugs with Year of FDA Approval
  • Targeted Therapy - The New Frontier of Cancer Treatment
  • Radiotherapy - Gaining Prominence
  • Innovations in Drug Delivery: A Key Factor in Product Differentiation
  • New Therapies Appear Over the Horizon
  • New Generation Prostate Cancer Drugs and Their Area of Use
  • Small Cap Companies: A Target of Private Capital Financing
  • Drugs (that are both available and under pipeline) Developed by the Three Small-Cap Companies
  • Minimally Invasive Devices Likely to Get Good Reception in Emerging Markets
  • Awareness Drives European Prostate Cancer Therapeutics Market
  • Growth Drivers
  • Rise in Prostate Cancer Incidences & Access to Modern Therapeutics Foster Growth
    • Table 2: New Incidences of Prostate Cancer (in '000) Worldwide for the years 2004 through 2007 (includes corresponding Graph/Chart)
    • Table 3: New Cancer Cases Diagnosed in the US in 2007: Percentage Share by Leading Cancer Sites (includes corresponding Graph/Chart)
  • Demographics & Lifestyles Raise the Risk of Prostate Cancer
    • Table 4: Probability of Developing Invasive Prostate Cancer by Age Group in the US (includes corresponding Graph/Chart)
    • Table 5: Male Population by Age Group in the US for the year 2007 (includes corresponding Graph/Chart)
  • Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
  • Unmet Needs Leave Scope for Further Research and Development
  • Supportive Cancer Drugs Contribute to Growth
    • Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
  • Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
    • Table 6: Five-Year Prostate Cancer Survival Rate in the US by Race, 1975-2002 (includes corresponding Graph/Chart)
    • Table 7: Five-Year Cancer Survival Rate Among US Males by Type - Prostate and Testis (1996-2002) (includes corresponding Graph/Chart)
    • Table 8: Five-Year Cancer Survival Rate (%) in the US by Race, 1996-2003 (includes corresponding Graph/Chart)
  • Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
  • Growth Restraints
  • Limited Tumor Specificity and Toxicity
  • Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
  • Multiple Drug Resistance
  • Stringent Regulations Delay Market Approval
    • Ongoing Clinical Trials in Hormone Refractory Prostate Cancer
  • Challenges Encountered in Clinical Trials
    • Notable Prostate Cancer Drug Failures in Phase III Development
  • High Development Costs Retracts Manufacturers in Developing Countries

2. Clinical Trials

  • Drugs in Pipeline
  • Select Prostate Cancer Drugs/Compounds in Pipeline
  • Select Prostate Cancer Drugs Under Phase II/III Trials by Leading Companies
  • Drugs in Pre-Clinical Stage
  • Select Prostate Cancer Drugs/Compounds in Pre-Clinical Stage
  • Commercially Available Drugs
  • Select Prostate Cancer Drugs (Commercially Available) by Leading Companies

3. Product Overview

  • Cancer: A Major Health Crises in the Modern World
    • Table 9: Mortality Rate in the US for the Year 2005 by Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory Diseases, and Accidents (Unintentional Injuries) (includes corresponding Graph/Chart)
    • Table 10: Mortality Rate in the US for the Year 2005: Percentage Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular diseases, Chronic lower respiratory diseases, Accidents (unintentional injuries), and Others (includes corresponding Graph/Chart)
    • Table 11: Cancer Death Rates in the US (2007): Percentage Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas, Leukemia, and Others (includes corresponding Graph/Chart)
    • Table 12: Comparison of Mortality Among African Americans and Whites by Cancer Type in the US, 2000- 2004 (includes corresponding Graph/Chart)
  • Prostate - Structure
  • Pituitary Gland
  • Testes
  • Prostate Cancer - A Primer
  • Key Facts to Gaze at
    • Table 13: Lifetime Probability of Developing Cancer (in Men) by Type in the US, 2002-2004
    • Table 14: New Incidences of Prostate Cancer (in '000) Worldwide for the years 2007 and 2008 (includes corresponding Graph/Chart)
    • Table 15: Mortality Due to Prostate Cancer (in '000) Worldwide for the Years 2007 and 2008 (includes corresponding Graph/Chart)
    • Table 16: Male Population (in Million) for the Year 2007 for Select Regions (includes corresponding Graph/Chart)
  • Screening/Detection of Prostate Cancer
  • Digital Rectal Exam (DRE)
  • Transrectal Ultrasound (TRUS)
  • PSA Blood Test
  • Strategies to Enhance Screening/Detection of Prostate Cancer
  • Improved PSA Testing
  • Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels
  • Insulin-like Growth Factor (IGF-1) and Intact IGF- Binding Protien-3 (IGF-BP3)
  • GSTP1 Methylation Levels and Prostate Cancer Diagnosis
  • Microbubble Ultrasound
  • Staging of Prostate Cancer
  • Gleason Score
    • Gleason Score and Grading of Prostate Cancer
  • TNM Staging
    • T-Staging Analysis of Prostate Cancer
  • Genetic & Non-Genetic Factors
  • Hereditary or Genetic Factors
  • Non-Genetic or Environmental Factors
    • Table 17: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity in US, 1999-2003 (includes corresponding Graph/Chart)
  • Prevention of Cancer
  • Role of Diet in Prostate Cancer

4. Treatment Options for Prostate Cancer

  • Hormonal Therapy
  • Medical Hormone Therapy
    • LHRH Analogs
      • Dose of LHRH Agonists for Advance Prostate Carcinoma Treatment
    • Anti-Androgens
      • Leading Non-Steroidal Anti-androgen Hormonal Therapy Drugs for Prostate Cancer
    • Anti-Androgen Monotherapy
  • Orchiectomy
    • Side Effects of Orchiectomy
  • Time to Start Hormonal Therapy
  • Strategies to Enhance Hormonal Treatment
    • Combination Therapy
    • Intermittent Therapy
  • Radiation Therapy
  • Brachytherapy
    • Treatment Procedure
    • Benefits of Brachytherapy
    • Drawbacks of Brachytherapy
    • High Dose Rate (HDR) Brachytherapy
  • External Beam Radiation Therapy (EBRT)
  • Side Effects of Radiotherapy
  • Strategies to Enhance Radiation Treatment
    • New Radiation Techniques
    • Whole Pelvic Radiation Therapy (WPRT)
    • New Radiation Devices
  • Chemotherapy
  • Risks Associated with Chemotherapy
  • Surgical Procedures for Prostate Cancer
  • Transurethral Resection of the Prostate (TURP)
  • Prostatectomy and Lymph Node Dissection
  • Radical Prostatectomy
  • Cryosurgery
    • Advantages of Cryosurgery
    • Disadvantages of Cryosurgery
  • Other Treatment Options
  • Intensity Modulated Radiation Therapy (IMRT)
    • Benefits of IMRT
    • Drawbacks of IMRT
  • Androgen Deprivation Therapy (ADT)
  • High Dose Radiation (HDR) Monotherapy
    • Drawbacks of HRD
  • Choosing the Optimal Treatment Method...
  • Recurrent Prostate Cancer
  • Recurrent Prostate Cancer Subsequent to Surgery
  • Recurrent Prostate Cancer Subsequent to Radiation Therapy
  • Hormone-Refractory Prostate Cancer (HRPC)
    • Select Drugs in Advanced Development Stage for Hormone-Refractory Prostate Cancer
    • Chemotherapy
      • TCaxotere(r) (Docetaxel)
      • Bone Complication Treatments
      • Bisphosphonate Drugs
      • Doxazosin, a Cytotoxic Drug for Prostate Cancer
    • Radiation Therapy
  • Strategies to Enhance Recurrent Prostate Cancer Treatment
    • Chemotherapy - New Regimens
    • Phase I Clinical Trials
    • Combination Therapy
    • Gene Therapy
    • Targeted Therapy
      • Selective Endothelia A Receptor Antagonist - (SERA(tm))
      • Other Select Targeted Therapies
      • Tyrosine Kinase Inhibitors
      • Anti-Angiogenic Drugs
      • Monoclonal Antibodies
      • Vaccines
      • Radioactive Monoclonal Antibodies

5. Drug Approvals and Clinical Studies

  • Debiopharm Unveils Results of Phase III Study of Trelstar in Prostate Cancer Treatment
  • Algeta to Start Clinical Study of Alpharadin in HRPC
  • Ferring Receives FDA Approval for Degarelix in Prostate Cancer
  • Isis and OncoGenex Reveals Positive results of OGX- 011 Molecule in HRPC
  • Antisoma Completes Phase 2 Study of ASA404 in Prostate Cancer
  • Cougar Conducts Phase I/II Clinical Trials on CB7630 in Patients with Prostate Cancer
  • Ambrilia Unveils Results of PCK3145 in Patients with Metastatic Prostate Cancer
  • Peregrine Pharmaceuticals Reveals Pre-Clinical Data on Bavituximab in Prostate Cancer
  • Cell Genesys Reveals Data of GVAX Immunotherapy for Treatment of Prostate Cancer
  • Bioponic Phytoceuticals Unveils Pre-Clinical Data on Curecumin(tm) for Prostate Cancer
  • New Study Reveals Cough Medicine - Noscapine to be Effective in Prostate Cancer
  • Fosamax(r) Found Effective in Preventing Bone Loss in Prostate Cancer Patients
  • Genta Unveils Results of Phase II Clinical Trial of Genasense(r) in Prostate Cancer
  • Cell Therapeutics Reveals Phase 2 Clinical Trial Results of XYOTAX(tm) in Androgen Independent Prostate Cancer Patients
  • Sanofi-Aventis' Taxotere(r) Enhances Survival in Metastatic Prostate Cancer Patients
  • NCI Initiates Phase 2 Clinical Trial of Cytogen's QUADRAMET for HRPC
  • Cleveland BioLabs to Initiate Phase II Clinical Trial for Curaxin in HRPC
  • NeoRx Begins Clinical Study for Picoplatin in Prostate Cancer
  • Novacea Starts Phase III Clinical Trial for Treatment of Prostate Cancer
  • Next Pharmaceuticals' Supplement Nexrutine Help Prevent Prostate Cancer
  • Antisoma Reveals Results from AS1404 Phase II Clinical Trial in HRPC
  • Marshall Edwards Conducts Study on Phenoxodiol in Prostate Cancer
  • Combination of Provenge(r) and Taxotere(r) Offer Better Results for HRPC Patients
  • Ambrilia Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy
  • University of California's Analyses Support Dendreon's Active Cellular Immunotherapy
  • Spectrum Announces Positive Outcome of Satraplatin Trial on HRPC Patients
  • Panacea Pharmaceuticals Identifies Blood Protein for Early Prostate Cancer Detection
  • Active Biotech Reveals Results of TASQ Phase I Study for Prostate Cancer
  • Positive Results of Combined Hormone and Radiation Therapies in Locally Advanced Prostate Cancer
  • Positive Results from Use of IMRT in Localized Prostate Cancer
  • Balanced Intake of Omega-6 and Omega-3 Fatty Acids Found to Reduce Prostate Cancer Growth
  • Sanofi's Taxotere Gains Approval from Nice of UK for Use in Late-Stage Prostate Cancer
  • Protox Gains Clearance from FDA to Conduct Phase I Trial of PRX302
  • Æterna Zentaris's Ozarelix Phase II Trial Shows Positive Results
  • Biomira Announces Results of Stimuvax Phase 2 Clinical Study
  • Cytogen Receives FDA Clearance for CYT-500 IND Application
  • US Researchers Unveils New Therapeutic Cancer Vaccine For Metastatic Prostate Cancer
  • PNNL and IsoRay Develops Cesium-131 Seed for Treatment of Prostate Cancer

6. Product Innovations/Introductions

  • Speciality European Pharma Introduces Plenaxis
  • Actavis Unveils Bicalutamide Tablets for Prostate Cancer in the European Markets
  • Artemis to Introduce IGRT
  • Immunomedics Introduces Immunotoxin for Treatment of Prostate and Lung Cancer
  • Barr Unveils Generic Version of Proscar(r) Tablets
  • IRX Therapeutics to Develop Vaccine for Prostate Cancer
  • Actavis Introduces New Generic Drugs in Europe
  • Robot-Assisted Radical Prostatectomy for Treatment of Prostate Cancer

7. Recent Industry Activity

  • Sanofi-Aventis Secures Approval of Japanese Health Ministry for Taxotere(r) Injection
  • Schering-Plough Terminates Collaboration with Novacea
  • Takeda Terminates JV Deal, Merges its Subsidiaries
  • Aureon Laboratories and Pfizer Announce Research Partnership
  • Celera Enters into Licensing Agreement with Merck
  • Celera Announces Demerger from Applera Corporation
  • GPC Biotech and Celgene Terminate Agreement for Satraplatin
  • EUSA Acquires Cytogen Corporation
  • Eisai Acquires MGI Pharma
  • BN ImmunoTherapeutics Enters into a Scientific Partnership with NCI
  • Morphotek(r) Enters into Licensing Agreement with NCI
  • ValiRx Acquires Exclusive Evaluation License from CRT for New Prostate Cancer Compound
  • Cell Genesys Forms Global Alliance with Takeda on GVAX Immunotherapy Development for Prostate Cancer
  • Sirnaomics Extends Partnership with GRL to Develop Multi-Targeted RNAi Therapeutic Products
  • Aureon and Pfizer to Collaborate on New Stage of Research Project
  • CancerPartners UK Collaborates with Spire Healthcare
  • Cougar Biotech Enters into an Agreement with US FDA
  • Scottish Scientists Receives Contract from Cancer Research UK
  • ValiRx Collaborates with University of Surrey on Prostate Cancer Diagnostics
  • ValiRx Subsidiary Extends Collaboration with Cancer Research Technology
  • MacroArray Partners with Abbott on PCADM-1 Test for Prostate Cancer
  • Novacea Enters into Agreement with Schering-Plough
  • Bayer to Stop Sale of Viadur - A Drug for Prostate Cancer
  • Sagemark Embarks on Radiation Therapy Venture
  • RTS Concludes Californian Radiation Therapy Center Acquisition
  • Radiation Therapy Takes Over a North Carolina Treatment Center
  • DRAXIMAGE and Med Discovery Enter into Research Collaboration
  • Core Oncology Completes Acquisition of Coloplast's Brachytherapy Business
  • Novacea Licenses Asenstar Prostate Cancer Drug to Schering-Plough
  • Bentley Receives Approval for Generic Version of Casodex
  • GSK Acquires Praecis Pharmaceuticals
  • Samaritan Acquires Metastatin Pharma
  • Champions Biotechnology Acquires Patent Rights for Potential Cancer Treatments
  • GPC Biotech Submits NDA for Treatment of Prostate Cancer
  • MedMira Inks Agreement to Take Over Rights of a New Marker Technology
  • Cell Genesys's GVAX Prostate Cancer-Treatment Attains FDA's Fast Track Tag
  • Envisioneering Medical Enters into Agreement with BrachySciences
  • Signet Enters into Agreement with AsymmetRx to Distribute 'Prostate-63' Tests
  • Mylan Pharmaceuticals Obtains FDA Approval for Finasteride's ANDA
  • Æterna Zentaris Enters into Agreement with Nippon Kayaku
  • Progenics Pharmaceuticals Broadens Association with Seattle Genetics
  • Diosynth and Dendreon Sign Multi-Year Commercial Supply Deal
  • Genstar Capital Completes Acquisition of OnCure
  • Generex Biotechnology Expands Antigen Express Cancer Trials
  • Progenics Pharmaceuticals Acquires PSMA Development Company
  • Schweizerhall Acquires Novosis
  • Misonix Expands into France with Sonablate(r) 500
  • Indevus Enters into Agreement to Takeover Valera
  • Oncobionic Receives FDA Clearance for Cancer Treatment Technology
  • Misonix Expands HIFU Business in Europe by Entering into Spain
  • Altana Divests Entire Stake in GPC Biotech
  • Ipsen Enters into Partnership with GTx to Develop and Market Acapodene in Europe
  • Egenix and Proteome Systems Collaborate to Develop Prostate Cancer Test Using Semen
  • Valera and Spepharm Partner to Market Vantas, and Supprelin-LA
  • SurModics and AbbeyMoor Collaborate to Develop Products to Treat Prostate Diseases
  • Dendreon Constructs Manufacturing Facility in New Jersey
  • MediGene Introduces Prostate Cancer Drug in Italian Market
  • Gen-Probe Introduces Innovative Test for Prostate Cancer in Europe
  • DRL Introduces Generic Version of Proscar
  • Ferring Partners with Astellas on Degarelix License for Prostate Cancer Treatment
  • Protox Acquires PRX321 Cancer Program from US Public Health Service and Neurocrine
  • Astex Collaborates with CRT and Newcastle University for New Drug Discovery
  • Miraculins and Duke University Enter into Collaboration
  • Bayer Receives Rights to Prostate Cancer and Transplantation Drug Test from Abbott
  • Encorium Group Signs Contract with Global Biopharmaceutical Company
  • Paladin Signs an Agreement with Watson for Supply and Sale of Trelstar(r)
  • BioWa Obtains License for Anti-FGF8 Antibody from Kyowa Hakko
  • OncoGenex and Isis Pharmaceuticals Expand Partnership
  • Caprion and AstraZ eneca Enter into Collaboration
  • Innovate Oncology and Prostagenics Enter into Capridine- Beta Development Agreement
  • Protein Design Labs Sublicenses Antibody-Drug Conjugates Development Rights to Genentech
  • National Cancer Institute Enters into Agreement with Illumina
  • Sosei Seeks Marketing Rights for Prostate Cancer Drug in Japan

8. Focus on Select Global Players

  • Abbott Laboratories (USA)
  • Æterna Zentaris Inc.
  • ALZA Corporation (USA)
  • Amgen Inc. (USA)
  • AstraZeneca PLC (UK)
  • Medimmune, LLC (USA)
  • Bristol-Myers Squibb Company (USA)
  • Cell Genesys Inc. (USA)
  • Dendreon Corporation (USA)
  • EUSA Pharma, (USA) Inc. (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genentech Inc. (USA)
  • GlaxoSmithKline Plc (UK)
  • Immunomedics, Inc. (USA)
  • Indevus Pharmaceuticals Inc. (USA)
  • Novartis AG (Switzerland)
  • OSI Pharmaceuticals, Inc. (USA)
  • Paladin Labs Inc. (Canada)
  • Pfizer Inc. (USA)
  • Progenics Pharmaceuticals, Inc. (USA)
  • Sanofi-Aventis SA (France)
  • Spectrum Pharmaceuticals, Inc. (USA)
  • Takeda Pharmaceutical Company Limited (Japan)

9. Global Market Perspective

    • Table 18: World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/ Country - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
    • Table 19: World 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

  • A. Market Analysis
    • Overview
      • A Surging US Prostate Cancer Therapeutics Market
    • Table 20: Probability of Developing Invasive Prostate Cancer by Age Group in the US (includes corresponding Graph/Chart)
    • Table 21: Male Population by Age Group in the US for the Year 2007 (includes corresponding Graph/Chart)
      • Cost of Cancer Drugs - A Major Concern in the US
      • Market Accelerators
      • Market Challenges
      • Market Inhibitors
    • Table 22: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in the US for 2007 (includes corresponding Graph/Chart)
    • Current and Future Analysis
    • Key Statistics
    • Table 23: Mortality Rate in the US for the Year 2005 by Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory Diseases, and Accidents (Unintentional Injuries) (includes corresponding Graph/Chart)
    • Table 24: Mortality Rate in the US for the Year 2005: Percentage Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular diseases, Chronic lower respiratory diseases, Accidents (unintentional injuries), and Others (includes corresponding Graph/Chart)
    • Table 25: Cancer Death Rates in the US (2007): Percentage Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas, Leukemia, and Others (includes corresponding Graph/Chart)
    • Table 26: New Cancer Cases Diagnosed in the US in 2007: Percentage Share by Leading Cancer Sites (includes corresponding Graph/Chart)
    • Table 27: New Cases of Prostate Cancer Diagnosed in the US: Breakdown by Leading States for the Years 2007 and 2008 (includes corresponding Graph/Chart)
    • Table 28: Mortality Due to Prostate Cancer in the US: Breakdown by Leading States for the Years 2007 and 2008 (includes corresponding Graph/Chart)
    • Table 29: Lifetime Probability of Developing Cancer (in Men) by Type in the US, 2002-2004
    • Table 30: Comparison of Mortality Among African Americans and Whites by Cancer Type in the US, 2000-2004 (includes corresponding Graph/Chart)
    • Table 31: Five-Year Prostate Cancer Survival Rate in the US by Race, 1975-2002 (includes corresponding Graph/Chart)
    • Table 32: Five-Year Cancer Survival Rate Among US Males by Type - Prostate and Testis (1996-2002) (includes corresponding Graph/Chart)
    • Table 33: Five-Year Cancer Survival Rate (%) in the US by Race, 1996-2003 (includes corresponding Graph/Chart)
    • Table 34: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity in US, 1999-2003 (includes corresponding Graph/Chart)
    • Clinical Trials
    • Product Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 35: US Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2. Europe

  • A. Market Analysis
    • Overview
      • Awareness Drives European Prostate Cancer Therapeutics Market
    • Table 36: New Cases of Prostate Cancer Diagnosed in Europe: Breakdown by Region/Country for the Years 2007 and 2008 (In '000) (includes corresponding Graph/Chart)
    • Table 37: Mortality Due to Prostate Cancer in Europe: Breakdown by Region/ Country for the Years 2007 and 2008 (In '000) (includes corresponding Graph/Chart)
    • Current and Future Analysis
    • Clinical Trial
    • Product Launches
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 38: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country - France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
    • Table 39: European 10-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2a. France

  • A. Market Analysis
    • Overview
    • Anti-Androgen and LHRH Analogs Drive the French Market
    • Current and Future Analysis
    • Clinical Trials
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 40: French Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2b. Germany

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launch
    • Strategic Corporate Developments
    • GPC Biotech AG - A Major Player
  • B. Market Analytics
    • Table 41: German Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2c. Italy

  • A. Market Analysis
    • Italian Prostate Cancer Therapeutics Market - An Overview
    • Current and Future Analysis
    • Clinical Trial
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 42: Italian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2d. The United Kingdom

  • A. Market Analysis
    • Overview
      • LHRH Analogs - The Market Driver
    • Current and Future Analysis
    • Clinical Trials
    • Product Launch
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 43: UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2e. Spain

  • A. Market Analysis
    • Overview
      • Spanish Prostate Cancer Therapeutics Market - On a Roll
    • Current and Future Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 44: Spanish Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2f. Rest of Europe

  • A. Market Analysis
    • Current and Future Analysis
    • Clinical Trials
    • Strategic Corporate Development
    • Select Players
  • B. Market Analytics
    • Table 45: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3. Rest of World

  • A. Market Analysis
    • Current and Future Analysis
    • A Peek into Canadian Market
    • Table 46: New Cases of Prostate Cancer Diagnosed in Canada (2008): Breakdown by Leading Province (includes corresponding Graph/Chart)
    • Table 47: Mortality Due to Prostate Cancer Diagnosed in Canada (2008): Breakdown by Leading Province (includes corresponding Graph/Chart)
    • Table 48: Prostate Cancer Market in Canada (2008): New Cases and Deaths Due to Prostate Cancer by Age Group
    • Ambrilia Unveils Results of PCK3145 in Patients with Metastatic Prostate Cancer
    • Ambrilia Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy
    • Select Canadian Players
    • A Glance into Other Select Markets
      • Minimally Invasive Devices Likely to Get Good Reception in Emerging Markets
      • Cancer Market in Asia
      • Australia
      • India
      • Japan
      • Malaysia
    • Table 49: New Cases of Prostate Cancer Diagnosed in Asia-Pacific: Breakdown by Region/Country for the Years 2007 and 2008 (includes corresponding Graph/Chart)
    • Table 50: Mortality Due to Prostate Cancer in Asia-Pacific: Breakdown by Region/ Country for the Years 2007 and 2008 (includes corresponding Graph/Chart)
      • Cancer Market in Latin America
      • Brazil
      • Mexico
      • Argentina
    • Table 51: New Cases of Prostate Cancer Diagnosed in Latin America: Breakdown by Region/Country for the Years 2007 and 2008 (includes corresponding Graph/Chart)
    • Table 52: Mortality Due to Prostate Cancer in Latin America: Breakdown by Region/ Country for the Years 2007 and 2008 (includes corresponding Graph/Chart)
    • Clinical Trial
    • Product Launch
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 53: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics Market with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top